BRPI0416355A - métodos para avaliar o risco de um paciente desenvolver uma reação adversa a droga, para desenvolver uma terapia para uma reação adversa induzida por uma droga, para avaliar o risco de um paciente desenvolver sjs, ten ou hss, e para identificar uma droga que induz sjs, ten ou hss - Google Patents

métodos para avaliar o risco de um paciente desenvolver uma reação adversa a droga, para desenvolver uma terapia para uma reação adversa induzida por uma droga, para avaliar o risco de um paciente desenvolver sjs, ten ou hss, e para identificar uma droga que induz sjs, ten ou hss

Info

Publication number
BRPI0416355A
BRPI0416355A BRPI0416355-9A BRPI0416355A BRPI0416355A BR PI0416355 A BRPI0416355 A BR PI0416355A BR PI0416355 A BRPI0416355 A BR PI0416355A BR PI0416355 A BRPI0416355 A BR PI0416355A
Authority
BR
Brazil
Prior art keywords
sjs
hla
developing
drug
patient
Prior art date
Application number
BRPI0416355-9A
Other languages
English (en)
Inventor
Yuan-Tsong Chen
Shuen-Iu Hung
Wen-Hung Chung
Jer-Yuarn Wu
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34552314&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0416355(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of BRPI0416355A publication Critical patent/BRPI0416355A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"MéTODOS PARA AVALIAR O RISCO DE UM PACIENTE DESENVOLVER UMA REAçãO ADVERSA A DROGA, PARA DESENVOLVER UMA TERAPIA PARA UMA REAçãO ADVERSA INDUZIDA POR UMA DROGA, PARA AVALIAR O RISCO DE UM PACIENTE DESENVOLVER SJS, TEN OU HSS, E PARA IDENTIFICAR UMA DROGA QUE INDUZ SJS, TEN OU HSS". A presente invenção provê um método de predizer o risco de um paciente desenvolver reações adversas a droga, particularmente a síndrome Stevens-Johnson (SJS), necrólise epidérmica tóxica (TEN) ou síndrome de hipersensibilidade a droga (HSS). Descobriu-se que um alelo HLA-13, HLA-B* 1502 associado com SJS/TEN, que são induzidos por uma variedade de drogas. A correlação com HLA-B* 1502 é muitíssimo significativa para SJS/TEN induzidos por carbamazepina, em que todos os pacientes testados têm o alelo HLA-13*1502. Além disso, outro alelo HLA13, HLA-B*5801, é particularmente associado com SJS/TEN ou HSS induzidos por alopurinol. Reações cutâneas mais suaves, tais como erupção maculopapular, eritema multiforme (EM), urticária e erupção por droga fixa, são particularmente associadas com um terceiro alelo, HLA-13*4601. Para qualquer um dos alelos, os marcadores genéticos (p. ex., marcadores HLA, microssatélite ou marcadores de polimorfismo de nucleotídeo simples), localizados entre a região DRB1 e HLA-A do haplótipo HLA-B específico, podem também ser usados para o teste.
BRPI0416355-9A 2003-11-10 2004-06-18 métodos para avaliar o risco de um paciente desenvolver uma reação adversa a droga, para desenvolver uma terapia para uma reação adversa induzida por uma droga, para avaliar o risco de um paciente desenvolver sjs, ten ou hss, e para identificar uma droga que induz sjs, ten ou hss BRPI0416355A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/705,245 US7470513B2 (en) 2003-11-10 2003-11-10 Risk assessment for adverse drug reactions
PCT/US2004/019435 WO2005047544A1 (en) 2003-11-10 2004-06-18 Risk assessment for adverse drug reactions

Publications (1)

Publication Number Publication Date
BRPI0416355A true BRPI0416355A (pt) 2007-03-13

Family

ID=34552314

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416355-9A BRPI0416355A (pt) 2003-11-10 2004-06-18 métodos para avaliar o risco de um paciente desenvolver uma reação adversa a droga, para desenvolver uma terapia para uma reação adversa induzida por uma droga, para avaliar o risco de um paciente desenvolver sjs, ten ou hss, e para identificar uma droga que induz sjs, ten ou hss

Country Status (16)

Country Link
US (5) US7470513B2 (pt)
EP (1) EP1697539B1 (pt)
CN (1) CN1902328B (pt)
AT (1) ATE476524T1 (pt)
AU (1) AU2004289951B2 (pt)
BR (1) BRPI0416355A (pt)
CA (1) CA2544369C (pt)
CY (1) CY1110760T1 (pt)
DE (1) DE602004028508D1 (pt)
DK (1) DK1697539T3 (pt)
ES (1) ES2347150T3 (pt)
PL (1) PL1697539T3 (pt)
PT (1) PT1697539E (pt)
SI (1) SI1697539T1 (pt)
TW (1) TWI287580B (pt)
WO (1) WO2005047544A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470513B2 (en) * 2003-11-10 2008-12-30 Academia Sinica Risk assessment for adverse drug reactions
US7127355B2 (en) * 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
US20090087854A1 (en) * 2007-09-27 2009-04-02 Perlegen Sciences, Inc. Methods for genetic analysis
US20060166224A1 (en) * 2005-01-24 2006-07-27 Norviel Vernon A Associations using genotypes and phenotypes
US7452689B2 (en) * 2005-05-20 2008-11-18 Mayo Foundation For Medical Education And Research Method for rapid determination of thiopurine methyltransferase activity
WO2007134235A2 (en) * 2006-05-11 2007-11-22 Academia Sinica Hla alleles associated with adverse drug reactions and methods for detecting such
EP2344892B8 (en) * 2008-10-01 2014-11-12 The Arizona Board Of Regents On Behalf Of The University Of Arizona Glucuronidated acetaminophen as a marker of hepatic disorders
CN102108382A (zh) * 2009-12-23 2011-06-29 上海主健生物工程有限公司 卡马西平致皮肤严重不良反应遗传检测
US8927462B2 (en) 2010-04-12 2015-01-06 Academia Sinica Method for identifying HLA complexes associated with adverse drug reactions
CN103827312B (zh) * 2011-06-23 2016-06-15 长庚医疗财团法人基隆长庚纪念医院 评估抗癫痫药物苯妥英引发药物不良反应风险的方法
CN105039579B (zh) * 2011-06-23 2018-10-02 长庚医疗财团法人基隆长庚纪念医院 用hla等位基因评估抗癫痫药物苯妥英引发药物过敏反应的方法
CN102296109A (zh) * 2011-06-30 2011-12-28 北京思尔成生物技术有限公司 HLA-B*1502基因的SYBR Green I检测方法及其专用引物与试剂盒
TW201307846A (zh) * 2011-08-02 2013-02-16 Chang Gung Medical Foundation Chang Gung Memorial Hospital at Keelung 評估抗癲癇藥物引發不良反應或過敏反應風險（ａｄｒ）的方法
US10370409B2 (en) 2011-10-25 2019-08-06 The Scripps Research Institute Synthesis of libraries of peptide tertiary amides
US20150225788A1 (en) * 2011-12-12 2015-08-13 Wen-Hung Chung Risk assessment for phenytoin-induced adverse drug reactions
CN102925567B (zh) * 2012-10-23 2013-12-11 山东省皮肤病性病防治研究所 Hla-b*1301等位基因的用途
WO2014093118A1 (en) 2012-12-11 2014-06-19 Albert Einstein College Of Medicine Of Yeshiva University Methods for high throughput receptor:ligand identification
JP2015107095A (ja) * 2013-03-14 2015-06-11 凸版印刷株式会社 眼合併症を伴う重症薬疹の発症リスクの評価方法
CN104818316B (zh) * 2013-11-28 2018-09-21 复旦大学 用于筛查柳氮磺胺吡啶所致皮肤药物不良反应的人类白细胞抗原基因检测试剂盒
CN103646185A (zh) * 2013-12-25 2014-03-19 顾德国 一种药品不良反应报告质量评估系统及方法
CN104017898B (zh) * 2014-06-25 2016-04-27 上海荻硕贝肯生物科技有限公司 快速检测hla-b*5801等位基因的引物、试剂盒及方法
KR101591603B1 (ko) * 2014-10-16 2016-02-04 연세대학교 산학협력단 약물유해반응 예측에 관한 정보 제공 방법
CN104450914A (zh) * 2014-12-10 2015-03-25 苏州旷远生物分子技术有限公司 用于检测人hla-b*1502基因的引物、探针、荧光pcr试剂盒和方法
US9927443B2 (en) 2015-04-10 2018-03-27 Conquerab Inc. Risk assessment for therapeutic drugs
US9932638B2 (en) 2015-06-29 2018-04-03 Millennium Health, LLC Single nucleotide polymorphism in HLA-B*15:02 and use thereof
US9903866B2 (en) 2016-04-05 2018-02-27 Conquerab Inc. Portable devices for detection of antibodies against therapeutic drugs
JP2019522466A (ja) 2016-05-18 2019-08-15 アルバート アインシュタイン カレッジ オブ メディシン，インコーポレイティド 変異ｐｄ−ｌ１ポリペプチド、ｔ細胞調節多量体ポリペプチド、及びそれらの使用方法
BR112018073606A2 (pt) 2016-05-18 2019-02-26 Cue Biopharma, Inc. polipeptídeos multiméricos moduladores de células t e métodos de uso dos mesmos
JP6395061B2 (ja) * 2016-06-21 2018-09-26 チャン グン メディカル ファンデーション チャン グン メモリアル ホスピタル アット キールン フェニトインによって誘発される薬の副作用のリスクを評価する方法
CN116970061A (zh) 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
WO2018129474A1 (en) 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3596118A4 (en) 2017-03-15 2021-04-07 Cue Biopharma, Inc. PROCESSES FOR MODULATING AN IMMUNE RESPONSE
US11289178B2 (en) 2017-04-21 2022-03-29 International Business Machines Corporation Identifying chemical substructures associated with adverse drug reactions
SG11202003391XA (en) * 2017-10-27 2020-05-28 Chang Gung Memorial Hospital Linkou Method for assessing the risk of cutaneous adverse drug reactions induced by anti-epileptic drug lamotrigine, detection reagent thereof and use thereof
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
CN108342457B (zh) * 2018-04-01 2021-12-07 广东辉锦创兴生物医学科技有限公司 Hla-b5801等位基因的检测试剂盒及其应用
CN108866007A (zh) * 2018-04-26 2018-11-23 厦门敖依生物科技有限公司 一种检测hla-b*5801的单克隆抗体及其制备方法与应用
US20220177968A1 (en) * 2019-03-12 2022-06-09 Chang Gung Memorial Hospital, Linkou Methods for detecting or reducing the incidence of adverse drug reactions
TWI804620B (zh) * 2019-05-06 2023-06-11 長庚醫療財團法人林口長庚紀念醫院 評估疾病調節抗風濕藥物引發嚴重皮膚藥物不良反應風險的方法、其檢測套組及其用途
CA3137521A1 (en) * 2019-05-06 2020-11-12 Chang Gung Memorial Hospital, Linkou Methods for assessing the risk of developing severe cutaneous adverse drug reactions induced by disease-modifying antirheumatic drugs, detection kit thereof and uses thereof
US11763946B2 (en) * 2020-02-27 2023-09-19 Optum, Inc. Graph-based predictive inference
CA3169949A1 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550039A (en) * 1995-03-07 1996-08-27 Hoffmann-La Roche Inc. Oligonucleotide primers for HLA class I B locus DNA typing
US6583139B1 (en) * 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US7470513B2 (en) * 2003-11-10 2008-12-30 Academia Sinica Risk assessment for adverse drug reactions

Also Published As

Publication number Publication date
EP1697539A1 (en) 2006-09-06
EP1697539B1 (en) 2010-08-04
ATE476524T1 (de) 2010-08-15
AU2004289951A1 (en) 2005-05-26
CY1110760T1 (el) 2015-06-10
CA2544369A1 (en) 2005-05-26
ES2347150T3 (es) 2010-10-26
CA2544369C (en) 2014-08-05
US20130330724A1 (en) 2013-12-12
US7964351B2 (en) 2011-06-21
PT1697539E (pt) 2010-10-04
CN1902328A (zh) 2007-01-24
SI1697539T1 (sl) 2010-11-30
US8012686B2 (en) 2011-09-06
US7470513B2 (en) 2008-12-30
PL1697539T3 (pl) 2010-12-31
AU2004289951B2 (en) 2009-10-22
TW200525038A (en) 2005-08-01
DE602004028508D1 (de) 2010-09-16
US20090053727A1 (en) 2009-02-26
DK1697539T3 (da) 2010-11-22
TWI287580B (en) 2007-10-01
WO2005047544A1 (en) 2005-05-26
US20120077192A1 (en) 2012-03-29
US9562268B2 (en) 2017-02-07
CN1902328B (zh) 2010-10-20
US20050100926A1 (en) 2005-05-12
US20080227109A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
BRPI0416355A (pt) métodos para avaliar o risco de um paciente desenvolver uma reação adversa a droga, para desenvolver uma terapia para uma reação adversa induzida por uma droga, para avaliar o risco de um paciente desenvolver sjs, ten ou hss, e para identificar uma droga que induz sjs, ten ou hss
Alghanim et al. Detection and evaluation of DNA methylation markers found at SCGN and KLF14 loci to estimate human age
BRPI0710436A8 (pt) método para determinar se um paciente é portador de hla-b*1502, kit para determinar se um paciente é portador de hla-b*1502,kit de três sondas para determinar se um paciente é portador de hla-b*1502, método para determinar se um paciente é portador de hla-b*5801, kit para determinar se um paciente é portador de hla-b*5801, kit de três sondas para determinar se um paciente é portador de hla-b*5801 e método para determinar se um composto é um candidato que induz uma reação adversa causada por droga (adr) em um paciente que é portador de um alelo de hla associado com a adr induzida por um droga
Reich et al. TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*‐857 independent of the PSORS1 risk allele
Vijai et al. A genome-wide association study of marginal zone lymphoma shows association to the HLA region
BR112014001258B1 (pt) Método de tipagem de dna, e, conjuntos de iniciadores para tipagem de dna
BR0308161A (pt) métodos para a detecção de distúrbios genéticos
De Castro et al. Genetic variants of the DDR1 gene are associated with vitiligo in two independent Brazilian population samples
He et al. Differentially methylated gene patterns between age‐matched sarcopenic and non‐sarcopenic women
He et al. Association between the HLA-B* 15: 02 allele and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han individuals of northeastern China
Leme et al. A survey of airway responsiveness in 36 inbred mouse strains facilitates gene mapping studies and identification of quantitative trait loci
Jahantigh et al. Genetic polymorphisms and haplotypes of the DJ-1 gene promoter associated with the susceptibility to male infertility
JP5899527B2 (ja) 第６染色体短腕２１．３３領域の一塩基多型に基づく抗てんかん薬による薬疹リスクの検査方法
Becker et al. Evidence for differences in DNA methylation between Germans and Japanese
Zajacova et al. Differences in promoter DNA methylation and mRNA expression of individual alleles of the HLA class II DQA1 gene
BR112022014681A2 (pt) Relógio epigenético para galliformes
Gianotti et al. Mitochondrial DNA copy number is modulated by genetic variation in the signal transducer and activator of transcription 3 (STAT3)
Giegling et al. Influence of neuronal cell adhesion molecule (NCAM1) variants on suicidal behaviour and correlated traits
Correa et al. HLA‐DR and DQB1 gene polymorphism in the North‐western Colombian population
Xiao et al. Association of HLA-DQA1 and DQB1 alleles with alolpecia areata in Chinese Hans
Jin et al. A novel mutation (c. 1010G> T; p. R337L) in TP63 as a cause of split‐hand/foot malformation with hypodontia
Periñán et al. The role of RHOT1 and RHOT2 genetic variation on Parkinson disease risk and onset
Chen et al. The novel HLA‐DQB1* 03: 282N allele was identified in a Chinese individual.
Calvo‐Ferrer et al. Identification of a novel HLA‐C* 07 allele, HLA‐C* 07: 943, in a Spanish individual.
Quan et al. Characterization of the novel HLA‐DQB1* 03: 362 allele in a Chinese family.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2311 DE 22-04-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.